With Omicron dominant, hospitals shift away from monoclonal antibody treatments
[ad_1] Just a few weeks ago, monoclonal antibodies were a major part of New Hampshire’s strategy to unburden overrun hospitals. The treatments, often administered in an outpatient setting via IV, bolster the body’s defense with synthetic immune cells to help patients fight COVID-19 without hospitalization. Until recently, the treatment dramatically decreased COVID-related hospitalizations, especially among […]
Continue Reading